MOESM4 of Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
收藏NIAID Data Ecosystem2026-03-10 收录
数据链接：
官方服务：
资源简介：
Additional file 4: Table S3. Sample details. Severity and site of toxicity (gastrointestinal (GI), endocrine, skin and/or other) and treatment termination status for baseline sera samples from anti-CTLA-4 (n = 39), anti-PD-1 (n = 28), and combination (n = 11) melanoma patients. Two anti-CTLA-4 patients were sampled twice (11-311, in 2011 and 2013; and 12-071, in 2012 and 2013), and one anti-PD-1 patient was sampled twice (13-185, in 2015 and 2016).
创建时间：
2018-04-02
